

TM CRUX European Fund

EUR factsheet June 2023

CRUX
ASSET MANAGEMENT

Fund Facts as at 30/06/23

Fund Objective

The Fund aims to achieve long-term capital growth by investing primarily in equities of European companies.

Launch Date

2 November 2015

Structure

OEIC

Fund Size¹

€66.5m

Performance comparator

IA Europe ex UK

Fund Base Currency

GBP

Share Class Currency

EUR

XD Dates

01-Jan, 01-April, 01-July, 01-Oct

Dividend Pay Dates

28-Feb, 31-May, 31-Aug, 30-Nov

¹The base currency of the fund is GBP and this figure has been calculated using the fx rate as at 28.02.2023

Market Capitalisation	(%)
> €10bn	74.6
€1bn-10bn	23.1
< €1bn	0.0


Charges (%)	Initial	OCF
I Class (EUR)	Nil	1.07

Minimum Investment	
I Class (EUR)	€100

ISIN Numbers (EUR)
GB00BYQJXG57 (I Acc)
GB00BYQJXH64 (I Inc)

Top 10 Holdings	%	Top 10 Countries	%	Top 10 Sectors	%
Novo Nordisk	6.3	France	22.0	Capital Goods	15.1
LVMH	5.4	Germany	18.3	Pharmaceuticals, Biotechnology & Life Sciences	14.4
ASML Holding	4.7	Switzerland	11.4	Semiconductors & Semiconductor Equipment	11.2
Schneider	4.0	Denmark	9.9	Banks	9.2
Nordea	3.5	Netherlands	9.6	Software & Services	8.8
Sampo	3.2	Finland	6.7	Consumer Durables & Apparel	8.5
STMicroelectronics	3.0	Ireland	4.7	Technology Hardware & Equipment	4.6
VAT Group	2.7	United Kingdom	3.5	Materials	3.7
Capgemini	2.7	Sweden	2.4	Commercial & Professional Services	3.6
Brenntag	2.7	Italy	2.4	Financial Services	3.6
Total Holdings	48	Cash	2.3		

Source: CRUX Asset Management.



Source: as at 30 June 2023. © 2023 FE. All Rights Reserved. Total return, Bid-bid in EUR, net income reinvested.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

TM CRUX European Fund

(Continued)



Disc Yr Perf* (%)	YTD	2022	2021	2020	2019	2018	Since launch
TM CEF I Acc EUR	11.3%	-19.0%	23.6%	5.3%	26.0%	-15.2%	43.7%
IA Europe ex UK	11.4%	-13.9%	23.4%	4.4%	27.5%	-13.1%	54.4%

Disc Yr Perf* (Discrete Year Performance)

Source: as at 30 June 2023. © 2023 FE. All Rights Reserved. Total return, Bid-bid in EUR, net income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

Note: These figures refer to the past and past performance is not a reliable indicator of future results.

The fund lagged its peer group due to being underweight in consumer discretionary which performed strongly. Our healthcare holdings also slipped back slightly such as Novo Nordisk, Merck and Eurofins. Bright spots included SoftwareOne which jumped 27% on a bid offer from Bain; we have retained our shares as both we and management consider the offer price to undervalue the business. Chip-makers STMicro and Infineon advanced on positive sentiment spilling over from artificial intelligence driving more demand as well as data showing that memory chip volumes have likely bottomed. Freight forwarders DSV and Kuehne continued to edge higher as investor sentiment becomes less bearish over profit yields remaining higher for longer, even if volume growth remains sluggish. Soitec put on 18% after fairly new management presented a capital markets day. In terms of transactions, we disposed of some residual positions in Total, DSM and UMG. We topped up Puma where sentiment had become too bearish, and subsequently management has hinted that guidance is unlikely to be reduced, leading to a share price recovery. We also started a position in Stedim, which makes critical components such as filters for drug production but which is suffering from significant customer de-stocking and leaving the share price languishing.



James Milne
Fund Manager



Richard Pease
Fund Manager

MSCI
ESG RATINGS



Produced by MSCI ESG Research as of 30 June 2023



MSCI ESG Research LLC's ("MSCI ESG") Fund Metrics and Ratings (the "information") provide environmental social and governance data with respect to underlying securities within more than 31,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.

Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX's research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX European Fund (the 'Fund') is a sub-fund of TM CRUX OEIC (the 'Company'). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 ('OEIC Regulations') in England and Wales under registry number IC001022. The Company is regulated by the FCA and was authorised on 10 December 2014. The FP CRUX European Fund was renamed the TM CRUX European Fund on 28 September 2019. This information is only directed at persons residing in jurisdictions where the Company and its shares are authorised for distribution or where no such authorisation is required. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website www.cruxam.com. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially to those shown on this document.

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 65 Curzon Street, London W1J 8PE. It is authorised and regulated by the Financial Conduct Authority (FRN 623757)

These figures refer to the past and past performance is not a reliable indicator of future results.

The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.

To obtain monthly commentary from our fund managers please visit: www.cruxam.com/news

